Elderly people with combined vision and hearing loss have a greater risk of developing dementia, according to a nationwide Korean study.
Researchers have found an alternative natalizumab administration route for patients with relapsing-remitting multiple sclerosis (RRMS), according to a prospective phase 2 study.
Fremanezumab treatment reduces headache severity and durations for patients with chronic migraine or episodic migraine, according to new findings presented at the American Academy of Neurology Annual Meeting.
Patients with Guillain-Barré syndrome with a poor prognosis do not benefit from a second intravenous immunoglobulin dose, according to a study published in The Lancet Neurology.
The first phase 3 trial comparing ponesimod to teriflunomide found ponesimod to be more effective at reducing the annualized relapse rate in multiple sclerosis (MS) patients.
The US Food and Drug Administration has recently approved ponesimod, an oral treatment, for adults with relapsing multiple sclerosis.
Onasemnogene abeparvovec yielded clinically meaningful responses and a favorable benefit-risk profile for patients with spinal muscular atrophy type 1, according to findings from a recent phase 3 trial.
Quality of life outcomes improved for patients treated with endovascular therapy 6 to 16 hours after stroke versus standard therapy alone, according to secondary analysis of the DEFUSE 3 randomized clinical trial.
Early findings suggest donanemab may slow cognitive decline in patients with early Alzheimer’s disease, according to results of a randomized, phase 2 trial.
Recent findings suggest that prehospital administration of tranexamic acid could lead to increased mortality in patients with isolated severe traumatic brain injury.